The Role of the Skin Microbiome in Acne: Challenges and Future Therapeutic Opportunities.

Alicja Nied��wiedzka, Maria Pia Micallef, Manuele Biazzo, Christine Podrini
Author Information
  1. Alicja Nied��wiedzka: The BioArte Ltd., Malta Life Science Park, Triq San Giljan, SGN 3000 San Gwann, Malta. ORCID
  2. Maria Pia Micallef: The BioArte Ltd., Malta Life Science Park, Triq San Giljan, SGN 3000 San Gwann, Malta. ORCID
  3. Manuele Biazzo: The BioArte Ltd., Malta Life Science Park, Triq San Giljan, SGN 3000 San Gwann, Malta.
  4. Christine Podrini: The BioArte Ltd., Malta Life Science Park, Triq San Giljan, SGN 3000 San Gwann, Malta. ORCID

Abstract

Acne vulgaris is a widespread dermatological condition that significantly affects the quality of life of adolescents and adults. Traditionally, acne pathogenesis has been linked to factors such as excess sebum production, follicular hyperkeratinization, and the presence of (). However, recent studies have highlighted the role of the skin microbiome, shifting focus from individual pathogens to microbial community dynamics. This review critically evaluates existing research on the skin microbiome and its relationship to acne, focusing on microbial diversity, strain variability, and emerging therapies targeting the microbiome. While certain studies associate with acne severity, others show this bacterium's presence in healthy skin, suggesting that strain-specific differences and overall microbial balance play crucial roles. Emerging therapeutic approaches, such as probiotics and bacteriophage therapy, aim to restore microbial equilibrium or selectively target pathogenic strains without disturbing the broader microbiome. However, the lack of standardized methodologies, limited longitudinal studies, and the narrow focus on bacterial communities are major limitations in current research. Future research should explore the broader skin microbiome, including fungi and viruses, use consistent methodologies, and focus on longitudinal studies to better understand microbial fluctuations over time. Addressing these gaps will enable the development of more effective microbiome-based treatments for acne. In conclusion, while microbiome-targeted therapies hold promise, further investigation is needed to validate their efficacy and safety, paving the way for innovative, personalized acne management strategies.

Keywords

References

  1. PLoS One. 2014 Aug 11;9(8):e104199 [PMID: 25111794]
  2. J Shoulder Elbow Surg. 2021 Jun;30(6):1410-1422 [PMID: 33373684]
  3. Dermatol Ther. 2021 Jan;34(1):e14609 [PMID: 33258536]
  4. Microbiologyopen. 2018 Apr;7(2):e00557 [PMID: 29193830]
  5. Trends Microbiol. 2013 Oct;21(10):510-5 [PMID: 23906500]
  6. Nat Rev Microbiol. 2018 Mar;16(3):143-155 [PMID: 29332945]
  7. J Dtsch Dermatol Ges. 2006 Apr;4(4):293-300 [PMID: 16638058]
  8. Front Microbiol. 2022 Jul 26;13:933189 [PMID: 35966676]
  9. Anaerobe. 2022 Aug;76:102580 [PMID: 35598875]
  10. J Invest Dermatol. 2015 Jan;135(1):110-118 [PMID: 25010142]
  11. PLoS Genet. 2015 Nov 05;11(11):e1005614 [PMID: 26539826]
  12. Microorganisms. 2023 Jan 22;11(2): [PMID: 36838255]
  13. Dermatology. 2014;228(1):86-92 [PMID: 24356463]
  14. J Invest Dermatol. 2013 Sep;133(9):2152-60 [PMID: 23337890]
  15. J Cosmet Dermatol. 2022 Oct;21(10):5092-5097 [PMID: 35384257]
  16. Expert Opin Drug Saf. 2022 Aug;21(8):1027-1037 [PMID: 35852102]
  17. Ann Dermatol. 2018 Feb;30(1):54-63 [PMID: 29386833]
  18. Acta Derm Venereol. 2018 Feb 7;98(2):262-267 [PMID: 29136261]
  19. BMC Dermatol. 2020 Nov 17;20(1):17 [PMID: 33203374]
  20. Nat Commun. 2013;4:1477 [PMID: 23403578]
  21. Health Technol Assess. 2024 Sep;28(56):1-86 [PMID: 39268864]
  22. J Clin Med. 2019 Jul 07;8(7): [PMID: 31284694]
  23. Clin Dermatol. 2021 Sep-Oct;39(5):829-839 [PMID: 34785010]
  24. Br J Dermatol. 2022 Oct;187(4):507-514 [PMID: 35553043]
  25. J Invest Dermatol. 2014 Nov;134(11):2747-2756 [PMID: 24820890]
  26. PLoS One. 2012;7(6):e38499 [PMID: 22723863]
  27. Antimicrob Agents Chemother. 2002 Jan;46(1):125-31 [PMID: 11751122]
  28. JAMA Dermatol. 2019 Apr 1;155(4):425-434 [PMID: 30758497]
  29. Eur J Clin Microbiol Infect Dis. 2020 Jul;39(7):1357-1364 [PMID: 32125556]
  30. Biofilm. 2021 Dec 09;4:100063 [PMID: 34950868]
  31. FEMS Microbiol Ecol. 2019 Feb 1;95(2): [PMID: 30590567]
  32. Cells. 2022 Dec 16;11(24): [PMID: 36552842]
  33. Clin Microbiol Rev. 2002 Jan;15(1):21-57 [PMID: 11781265]
  34. Am J Clin Dermatol. 2022 Jan;23(1):69-81 [PMID: 34751927]
  35. J Dermatol. 2012 Jul;39(7):613-6 [PMID: 22229642]
  36. Exp Dermatol. 2018 Jan;27(1):30-36 [PMID: 28636791]
  37. Arch Dermatol Res. 2006 Jan;297(7):280-8 [PMID: 16283346]
  38. Front Microbiol. 2022 May 31;13:901911 [PMID: 35711781]
  39. Infect Agent Cancer. 2022 May 30;17(1):23 [PMID: 35637508]
  40. J Dermatol. 2012 Oct;39(10):833-7 [PMID: 22779738]
  41. Sci Rep. 2018 Aug 6;8(1):11766 [PMID: 30082920]
  42. Sci Transl Med. 2021 Dec 22;13(625):eabd8077 [PMID: 34936382]
  43. BMJ. 2023 May 16;381:e074349 [PMID: 37192767]
  44. Acta Derm Venereol. 2024 May 15;104:adv33206 [PMID: 38751177]
  45. J Investig Dermatol Symp Proc. 2005 Dec;10(3):295-7 [PMID: 16382685]
  46. Drugs. 2019 Nov;79(17):1905-1909 [PMID: 31713811]
  47. Exp Dermatol. 2023 Jul;32(7):955-964 [PMID: 36999947]
  48. Nature. 2013 Jun 20;498(7454):367-70 [PMID: 23698366]
  49. J Dermatol. 2017 Nov;44(11):1248-1254 [PMID: 28623856]
  50. J Invest Dermatol. 2014 Mar;134(3):677-685 [PMID: 24157462]
  51. Cell Host Microbe. 2019 Mar 13;25(3):389-403.e6 [PMID: 30870621]
  52. Pediatr Dermatol. 2017 Nov;34(6):661-664 [PMID: 29024079]
  53. Expert Opin Pharmacother. 2009 Oct;10(15):2555-62 [PMID: 19761357]
  54. Cell. 2016 May 5;165(4):854-66 [PMID: 27153496]
  55. Nat Commun. 2023 Feb 22;14(1):1005 [PMID: 36813793]
  56. Int J Mol Sci. 2019 Apr 12;20(8): [PMID: 31013709]
  57. Expert Rev Clin Immunol. 2021 Apr;17(4):301-308 [PMID: 33616473]
  58. Eur Rev Med Pharmacol Sci. 2018 Jul;22(14):4411-4418 [PMID: 30058676]
  59. Exp Dermatol. 2014 Sep;23(9):687-9 [PMID: 24980271]
  60. J Am Acad Dermatol. 1983 Jan;8(1):41-5 [PMID: 6219134]
  61. Microorganisms. 2022 Jun 16;10(6): [PMID: 35744757]
  62. J Am Acad Dermatol. 2016 Feb;74(2):273-9 [PMID: 26525749]
  63. mBio. 2015 Oct 20;6(5):e01578-15 [PMID: 26489866]
  64. Mar Pollut Bull. 2019 Aug;145:595-603 [PMID: 31590829]
  65. Br J Dermatol. 2000 May;142(5):885-92 [PMID: 10809844]
  66. Dermatol Ther (Heidelb). 2022 Feb;12(2):577-589 [PMID: 35061237]
  67. Cutis. 1976 Mar;17(3):593-6 [PMID: 138553]
  68. Plast Reconstr Surg. 2021 Jan 1;147(1S-2):50S-61S [PMID: 33347075]
  69. J Am Acad Dermatol. 2024 May;90(5):1006.e1-1006.e30 [PMID: 38300170]
  70. Sci Transl Med. 2022 Feb 16;14(632):eabh1478 [PMID: 35171653]
  71. J Invest Dermatol. 2014 Feb;134(2):381-388 [PMID: 23884315]
  72. J Eur Acad Dermatol Venereol. 2018 Jun;32 Suppl 2:5-14 [PMID: 29894579]
  73. J Invest Dermatol. 2019 Mar;139(3):732-735 [PMID: 30579608]
  74. Front Cell Infect Microbiol. 2022 Jan 13;11:809792 [PMID: 35155271]
  75. Chin Med J (Engl). 2010 Mar 5;123(5):628-32 [PMID: 20367993]
  76. Nutrients. 2021 Apr 19;13(4): [PMID: 33921829]
  77. J Antimicrob Chemother. 2018 Jun 1;73(suppl_6):vi17-vi29 [PMID: 29878219]
  78. J Invest Dermatol. 2018 May;138(5):1137-1145 [PMID: 29246799]
  79. Sci Rep. 2016 Dec 21;6:39491 [PMID: 28000755]
  80. Int J Dermatol. 2024 Jun;63(6):806-815 [PMID: 38685118]
  81. Int J Mol Sci. 2023 Jan 31;24(3): [PMID: 36769020]
  82. J Eur Acad Dermatol Venereol. 2020 Jan;34(1):166-173 [PMID: 31306527]
  83. Dermatology. 2007;215(3):213-8 [PMID: 17823518]
  84. J Invest Dermatol. 2020 Aug;140(8):1619-1628.e2 [PMID: 31981578]
  85. PLoS One. 2016 Nov 30;11(11):e0167237 [PMID: 27902761]
  86. J Dermatol. 2016 Aug;43(8):906-11 [PMID: 26705192]
  87. Am J Clin Dermatol. 2017 Apr;18(2):169-191 [PMID: 28155090]
  88. Front Immunol. 2017 Nov 22;8:1614 [PMID: 29213272]
  89. J Drugs Dermatol. 2024 Jan 1;23(1):1278-1283 [PMID: 38206145]
  90. J Eur Acad Dermatol Venereol. 2017 Sep;31(9):e398-e399 [PMID: 28295699]
  91. J Am Acad Dermatol. 2016 May;74(5):945-73.e33 [PMID: 26897386]
  92. Front Immunol. 2024 Jan 31;15:1275269 [PMID: 38357543]
  93. Br J Dermatol. 2002 May;146(5):840-8 [PMID: 12000382]
  94. J Shoulder Elbow Surg. 2018 Sep;27(9):1539-1544 [PMID: 30054245]
  95. PeerJ. 2022 Jul 25;10:e13553 [PMID: 35910763]
  96. Cell Host Microbe. 2013 Apr 17;13(4):477-88 [PMID: 23601109]
  97. Pathogens. 2020 Jan 30;9(2): [PMID: 32019186]
  98. Clin Cosmet Investig Dermatol. 2018 Oct 08;11:445-449 [PMID: 30349341]
  99. Clin Dermatol. 2017 Mar - Apr;35(2):173-178 [PMID: 28274355]
  100. J Lipids. 2018 Sep 2;2018:5954034 [PMID: 30245886]
  101. J Drugs Dermatol. 2016 Jun 1;15(6):677-83 [PMID: 27272073]
  102. Life (Basel). 2022 Mar 15;12(3): [PMID: 35330173]
  103. Nat Rev Dis Primers. 2015 Sep 17;1:15029 [PMID: 27189872]
  104. Skin Health Dis. 2022 Jan 28;2(2):e93 [PMID: 35677920]
  105. J Eur Acad Dermatol Venereol. 2016 Aug;30(8):1261-8 [PMID: 27514932]
  106. Microorganisms. 2023 Feb 07;11(2): [PMID: 36838382]
  107. J Cosmet Dermatol. 2023 Oct;22(10):2650-2662 [PMID: 37550898]
  108. Microorganisms. 2021 Mar 18;9(3): [PMID: 33803499]
  109. Ann Pharmacother. 2021 Jan;55(1):111-116 [PMID: 32567361]

Grants

  1. R&I-2022-019L/XjenzaMalta

MeSH Term

Humans
Acne Vulgaris
Microbiota
Skin
Probiotics
Propionibacterium acnes

Word Cloud

Created with Highcharts 10.0.0acnemicrobiomeskinmicrobialstudiesfocusresearchtherapiesvulgarispresenceHoweverprobioticsbroadermethodologieslongitudinalFuturemicrobiome-targetedAcnewidespreaddermatologicalconditionsignificantlyaffectsqualitylifeadolescentsadultsTraditionallypathogenesislinkedfactorsexcesssebumproductionfollicularhyperkeratinizationrecenthighlightedroleshiftingindividualpathogenscommunitydynamicsreviewcriticallyevaluatesexistingrelationshipfocusingdiversitystrainvariabilityemergingtargetingcertainassociateseverityothersshowbacterium'shealthysuggestingstrain-specificdifferencesoverallbalanceplaycrucialrolesEmergingtherapeuticapproachesbacteriophagetherapyaimrestoreequilibriumselectivelytargetpathogenicstrainswithoutdisturbinglackstandardizedlimitednarrowbacterialcommunitiesmajorlimitationscurrentexploreincludingfungivirusesuseconsistentbetterunderstandfluctuationstimeAddressinggapswillenabledevelopmenteffectivemicrobiome-basedtreatmentsconclusionholdpromiseinvestigationneededvalidateefficacysafetypavingwayinnovativepersonalizedmanagementstrategiesRoleSkinMicrobiomeAcne:ChallengesTherapeuticOpportunitiesCacnes

Similar Articles

Cited By